iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
Provided By GlobeNewswire
Last update: May 13, 2025
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival
– Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program
Read more at globenewswire.com10.02
-0.08 (-0.79%)
Find more stocks in the Stock Screener
ITOS Latest News and Analysis
20 days ago - ChartmillThese stocks are gapping in today's sessionLet's have a look at the gap up and gap down stocks in today's session.
